APO Research
Talk to an analyst

APO RESEARCH · REPORT

Polycythemia Vera Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Polycythemia Vera Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025191 pages

Choose your research edition.

Industry ResearchPolycythemia Vera Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Polycythemia Vera Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Polycythemia Vera Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Polycythemia Vera Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Polycythemia Vera Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Polycythemia Vera Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Polycythemia Vera Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Polycythemia Vera Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Polycythemia Vera Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Polycythemia Vera Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Polycythemia Vera Drug include ANP Technologies, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Galena Biopharma, Inc., Gilead Sciences, Inc., Italfarmaco S.p.A., Karus Therapeutics Limited, miRagen Therapeutics, Inc. and Nerviano Medical Sciences S.r.l., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Polycythemia Vera Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Polycythemia Vera Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Polycythemia Vera Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Polycythemia Vera Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Polycythemia Vera Drug Segment by Company

ANP Technologies, Inc.

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd.

Galena Biopharma, Inc.

Gilead Sciences, Inc.

Italfarmaco S.p.A.

Karus Therapeutics Limited

miRagen Therapeutics, Inc.

Nerviano Medical Sciences S.r.l.

PharmaEssentia Corporation

Novartis AG

Teva Pharmaceutical Industries Ltd.

Polycythemia Vera Drug Segment by Type

Idelalisib

Givinostat

Dasatinib

M-009

Others

Polycythemia Vera Drug Segment by Application

Clinic

Hospital

Others

Polycythemia Vera Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Polycythemia Vera Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Polycythemia Vera Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Polycythemia Vera Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Polycythemia Vera Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Polycythemia Vera Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Polycythemia Vera Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Polycythemia Vera Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Polycythemia Vera Drug Industry Trends Table 2. Polycythemia Vera Drug Industry Drivers Table 3. Polycythemia Vera Drug Industry Opportunities and Challenges Table 4. Polycythemia Vera Drug Industry Restraints Table 5. Global Polycythemia Vera Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Polycythemia Vera Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Polycythemia Vera Drug Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Polycythemia Vera Drug Sales Market Share by Manufacturers Table 9. Global Polycythemia Vera Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Polycythemia Vera Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Polycythemia Vera Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Polycythemia Vera Drug Manufacturers, Product Type & Application Table 13. Global Polycythemia Vera Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Polycythemia Vera Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Idelalisib Table 17. Major Manufacturers of Givinostat Table 18. Major Manufacturers of Dasatinib Table 19. Major Manufacturers of M-009 Table 20. Major Manufacturers of Others Table 21. Global Polycythemia Vera Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Polycythemia Vera Drug Sales by Type (2021-2026) & (W Units) Table 23. Global Polycythemia Vera Drug Sales by Type (2027-2032) & (W Units) Table 24. Global Polycythemia Vera Drug Sales Market Share by Type (2021-2026) Table 25. Global Polycythemia Vera Drug Sales Market Share by Type (2027-2032) Table 26. Global Polycythemia Vera Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 27. Global Polycythemia Vera Drug Revenue by Type (2021-2026) & (W Units) Table 28. Global Polycythemia Vera Drug Revenue by Type (2027-2032) & (W Units) Table 29. Global Polycythemia Vera Drug Revenue Market Share by Type (2021-2026) Table 30. Global Polycythemia Vera Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Others Table 34. Global Polycythemia Vera Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Polycythemia Vera Drug Sales by Application (2021-2026) & (W Units) Table 36. Global Polycythemia Vera Drug Sales by Application (2027-2032) & (W Units) Table 37. Global Polycythemia Vera Drug Sales Market Share by Application (2021-2026) Table 38. Global Polycythemia Vera Drug Sales Market Share by Application (2027-2032) Table 39. Global Polycythemia Vera Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 40. Global Polycythemia Vera Drug Revenue by Application (2021-2026) & (W Units) Table 41. Global Polycythemia Vera Drug Revenue by Application (2027-2032) & (W Units) Table 42. Global Polycythemia Vera Drug Revenue Market Share by Application (2021-2026) Table 43. Global Polycythemia Vera Drug Revenue Market Share by Application (2027-2032) Table 44. Global Polycythemia Vera Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Polycythemia Vera Drug Sales by Region (2021-2026) & (W Units) Table 46. Global Polycythemia Vera Drug Sales Market Share by Region (2021-2026) Table 47. Global Polycythemia Vera Drug Sales Forecasted by Region (2027-2032) & (W Units) Table 48. Global Polycythemia Vera Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Polycythemia Vera Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 50. North America Polycythemia Vera Drug Sales by Country (2021-2026) & (W Units) Table 51. North America Polycythemia Vera Drug Sales by Country (2027-2032) & (W Units) Table 52. Europe Polycythemia Vera Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 53. Europe Polycythemia Vera Drug Sales by Country (2021-2026) & (W Units) Table 54. Europe Polycythemia Vera Drug Sales by Country (2027-2032) & (W Units) Table 55. Asia Pacific Polycythemia Vera Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. Asia Pacific Polycythemia Vera Drug Sales by Country (2021-2026) & (W Units) Table 57. Asia Pacific Polycythemia Vera Drug Sales by Country (2027-2032) & (W Units) Table 58. South America, Middle East and Africa Polycythemia Vera Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. South America, Middle East and Africa Polycythemia Vera Drug Sales by Country (2021-2026) & (W Units) Table 60. South America, Middle East and Africa Polycythemia Vera Drug Sales by Country (2027-2032) & (W Units) Table 61. Global Polycythemia Vera Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Polycythemia Vera Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Polycythemia Vera Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Polycythemia Vera Drug Revenue Market Share by Region (2021-2026) Table 65. Global Polycythemia Vera Drug Revenue Market Share by Region (2027-2032) Table 66. ANP Technologies, Inc. Company Information Table 67. ANP Technologies, Inc. Business Overview Table 68. ANP Technologies, Inc. Polycythemia Vera Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. ANP Technologies, Inc. Polycythemia Vera Drug Product Portfolio Table 70. ANP Technologies, Inc. Recent Development Table 71. Bristol-Myers Squibb Company Company Information Table 72. Bristol-Myers Squibb Company Business Overview Table 73. Bristol-Myers Squibb Company Polycythemia Vera Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Bristol-Myers Squibb Company Polycythemia Vera Drug Product Portfolio Table 75. Bristol-Myers Squibb Company Recent Development Table 76. F. Hoffmann-La Roche Ltd. Company Information Table 77. F. Hoffmann-La Roche Ltd. Business Overview Table 78. F. Hoffmann-La Roche Ltd. Polycythemia Vera Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. F. Hoffmann-La Roche Ltd. Polycythemia Vera Drug Product Portfolio Table 80. F. Hoffmann-La Roche Ltd. Recent Development Table 81. Galena Biopharma, Inc. Company Information Table 82. Galena Biopharma, Inc. Business Overview Table 83. Galena Biopharma, Inc. Polycythemia Vera Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Galena Biopharma, Inc. Polycythemia Vera Drug Product Portfolio Table 85. Galena Biopharma, Inc. Recent Development Table 86. Gilead Sciences, Inc. Company Information Table 87. Gilead Sciences, Inc. Business Overview Table 88. Gilead Sciences, Inc. Polycythemia Vera Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Gilead Sciences, Inc. Polycythemia Vera Drug Product Portfolio Table 90. Gilead Sciences, Inc. Recent Development Table 91. Italfarmaco S.p.A. Company Information Table 92. Italfarmaco S.p.A. Business Overview Table 93. Italfarmaco S.p.A. Polycythemia Vera Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Italfarmaco S.p.A. Polycythemia Vera Drug Product Portfolio Table 95. Italfarmaco S.p.A. Recent Development Table 96. Karus Therapeutics Limited Company Information Table 97. Karus Therapeutics Limited Business Overview Table 98. Karus Therapeutics Limited Polycythemia Vera Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Karus Therapeutics Limited Polycythemia Vera Drug Product Portfolio Table 100. Karus Therapeutics Limited Recent Development Table 101. miRagen Therapeutics, Inc. Company Information Table 102. miRagen Therapeutics, Inc. Business Overview Table 103. miRagen Therapeutics, Inc. Polycythemia Vera Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. miRagen Therapeutics, Inc. Polycythemia Vera Drug Product Portfolio Table 105. miRagen Therapeutics, Inc. Recent Development Table 106. Nerviano Medical Sciences S.r.l. Company Information Table 107. Nerviano Medical Sciences S.r.l. Business Overview Table 108. Nerviano Medical Sciences S.r.l. Polycythemia Vera Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Nerviano Medical Sciences S.r.l. Polycythemia Vera Drug Product Portfolio Table 110. Nerviano Medical Sciences S.r.l. Recent Development Table 111. PharmaEssentia Corporation Company Information Table 112. PharmaEssentia Corporation Business Overview Table 113. PharmaEssentia Corporation Polycythemia Vera Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. PharmaEssentia Corporation Polycythemia Vera Drug Product Portfolio Table 115. PharmaEssentia Corporation Recent Development Table 116. Novartis AG Company Information Table 117. Novartis AG Business Overview Table 118. Novartis AG Polycythemia Vera Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Novartis AG Polycythemia Vera Drug Product Portfolio Table 120. Novartis AG Recent Development Table 121. Teva Pharmaceutical Industries Ltd. Company Information Table 122. Teva Pharmaceutical Industries Ltd. Business Overview Table 123. Teva Pharmaceutical Industries Ltd. Polycythemia Vera Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Teva Pharmaceutical Industries Ltd. Polycythemia Vera Drug Product Portfolio Table 125. Teva Pharmaceutical Industries Ltd. Recent Development Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Polycythemia Vera Drug Distributors List Table 129. Polycythemia Vera Drug Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Polycythemia Vera Drug Product Image Figure 2. Global Polycythemia Vera Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Polycythemia Vera Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Polycythemia Vera Drug Sales (2021-2032) & (W Units) Figure 5. Global Polycythemia Vera Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Polycythemia Vera Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Idelalisib Image Figure 9. Givinostat Image Figure 10. Dasatinib Image Figure 11. M-009 Image Figure 12. Others Image Figure 13. Global Polycythemia Vera Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Polycythemia Vera Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Polycythemia Vera Drug Sales Market Share by Type (2021-2032) Figure 16. Global Polycythemia Vera Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Polycythemia Vera Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Polycythemia Vera Drug Revenue Market Share by Type (2021-2032) Figure 19. Clinic Image Figure 20. Hospital Image Figure 21. Others Image Figure 22. Global Polycythemia Vera Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Polycythemia Vera Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Polycythemia Vera Drug Sales Market Share by Application (2021-2032) Figure 25. Global Polycythemia Vera Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global Polycythemia Vera Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Polycythemia Vera Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 29. North America Polycythemia Vera Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Canada Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Mexico Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Europe Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Europe Polycythemia Vera Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 36. France Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 37. U.K. Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Italy Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Netherlands Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Asia Pacific Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Asia Pacific Polycythemia Vera Drug Sales Market Share by Country (2021-2032) Figure 42. China Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Japan Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 44. South Korea Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Southeast Asia Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 46. India Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 47. Australia Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South America, Middle East and Africa Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South America, Middle East and Africa Polycythemia Vera Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 51. South Africa Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Saudi Arabia Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Turkey Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Argentina Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 55. UAE Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Egypt Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Chile Polycythemia Vera Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Global Polycythemia Vera Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Polycythemia Vera Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Polycythemia Vera Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Polycythemia Vera Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Polycythemia Vera Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Polycythemia Vera Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Polycythemia Vera Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Polycythemia Vera Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Polycythemia Vera Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Polycythemia Vera Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Polycythemia Vera Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Polycythemia Vera Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Idelalisib
  • Givinostat
  • Dasatinib
  • M-009
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • ANP Technologies, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Galena Biopharma, Inc.
  • Gilead Sciences, Inc.
  • Italfarmaco S.p.A.
  • Karus Therapeutics Limited
  • miRagen Therapeutics, Inc.
  • Nerviano Medical Sciences S.r.l.
  • PharmaEssentia Corporation
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Polycythemia Vera Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Polycythemia Vera Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Polycythemia Vera Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Polycythemia Vera Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Polycythemia Vera Drug Market Dynamics
  1. 2.1 Polycythemia Vera Drug Industry Trends
  2. 2.2 Polycythemia Vera Drug Industry Drivers
  3. 2.3 Polycythemia Vera Drug Industry Opportunities and Challenges
  4. 2.4 Polycythemia Vera Drug Industry Restraints
3 Polycythemia Vera Drug Market by Manufacturers
  1. 3.1 Global Polycythemia Vera Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Polycythemia Vera Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Polycythemia Vera Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Polycythemia Vera Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Polycythemia Vera Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Polycythemia Vera Drug Manufacturers, Product Type & Application
  7. 3.7 Global Polycythemia Vera Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Polycythemia Vera Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Polycythemia Vera Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Polycythemia Vera Drug Tier 1, Tier 2, and Tier 3
4 Polycythemia Vera Drug Market by Type
  1. 4.1 Polycythemia Vera Drug Type Introduction
  2. 4.1.1 Idelalisib
  3. 4.1.2 Givinostat
  4. 4.1.3 Dasatinib
  5. 4.1.4 M-009
  6. 4.1.5 Others
  7. 4.2 Global Polycythemia Vera Drug Sales by Type
  8. 4.2.1 Global Polycythemia Vera Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Polycythemia Vera Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Polycythemia Vera Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Polycythemia Vera Drug Revenue by Type
  12. 4.3.1 Global Polycythemia Vera Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Polycythemia Vera Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Polycythemia Vera Drug Revenue Market Share by Type (2021-2032)
5 Polycythemia Vera Drug Market by Application
  1. 5.1 Polycythemia Vera Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Polycythemia Vera Drug Sales by Application
  6. 5.2.1 Global Polycythemia Vera Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Polycythemia Vera Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Polycythemia Vera Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Polycythemia Vera Drug Revenue by Application
  10. 5.3.1 Global Polycythemia Vera Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Polycythemia Vera Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Polycythemia Vera Drug Revenue Market Share by Application (2021-2032)
6 Global Polycythemia Vera Drug Sales by Region
  1. 6.1 Global Polycythemia Vera Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Polycythemia Vera Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Polycythemia Vera Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Polycythemia Vera Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Polycythemia Vera Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Polycythemia Vera Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Polycythemia Vera Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Polycythemia Vera Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Polycythemia Vera Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Polycythemia Vera Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Polycythemia Vera Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Polycythemia Vera Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Polycythemia Vera Drug Revenue by Region
  1. 7.1 Global Polycythemia Vera Drug Revenue by Region
  2. 7.1.1 Global Polycythemia Vera Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Polycythemia Vera Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Polycythemia Vera Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Polycythemia Vera Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Polycythemia Vera Drug Revenue (2021-2032)
  8. 7.2.2 North America Polycythemia Vera Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Polycythemia Vera Drug Revenue (2021-2032)
  11. 7.3.2 Europe Polycythemia Vera Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Polycythemia Vera Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Polycythemia Vera Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Polycythemia Vera Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Polycythemia Vera Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 ANP Technologies, Inc.
  2. 8.1.1 ANP Technologies, Inc. Company Information
  3. 8.1.2 ANP Technologies, Inc. Business Overview
  4. 8.1.3 ANP Technologies, Inc. Polycythemia Vera Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ANP Technologies, Inc. Polycythemia Vera Drug Product Portfolio
  6. 8.1.5 ANP Technologies, Inc. Recent Developments
  7. 8.2 Bristol-Myers Squibb Company
  8. 8.2.1 Bristol-Myers Squibb Company Company Information
  9. 8.2.2 Bristol-Myers Squibb Company Business Overview
  10. 8.2.3 Bristol-Myers Squibb Company Polycythemia Vera Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb Company Polycythemia Vera Drug Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Company Recent Developments
  13. 8.3 F. Hoffmann-La Roche Ltd.
  14. 8.3.1 F. Hoffmann-La Roche Ltd. Company Information
  15. 8.3.2 F. Hoffmann-La Roche Ltd. Business Overview
  16. 8.3.3 F. Hoffmann-La Roche Ltd. Polycythemia Vera Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 F. Hoffmann-La Roche Ltd. Polycythemia Vera Drug Product Portfolio
  18. 8.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
  19. 8.4 Galena Biopharma, Inc.
  20. 8.4.1 Galena Biopharma, Inc. Company Information
  21. 8.4.2 Galena Biopharma, Inc. Business Overview
  22. 8.4.3 Galena Biopharma, Inc. Polycythemia Vera Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Galena Biopharma, Inc. Polycythemia Vera Drug Product Portfolio
  24. 8.4.5 Galena Biopharma, Inc. Recent Developments
  25. 8.5 Gilead Sciences, Inc.
  26. 8.5.1 Gilead Sciences, Inc. Company Information
  27. 8.5.2 Gilead Sciences, Inc. Business Overview
  28. 8.5.3 Gilead Sciences, Inc. Polycythemia Vera Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Gilead Sciences, Inc. Polycythemia Vera Drug Product Portfolio
  30. 8.5.5 Gilead Sciences, Inc. Recent Developments
  31. 8.6 Italfarmaco S.p.A.
  32. 8.6.1 Italfarmaco S.p.A. Company Information
  33. 8.6.2 Italfarmaco S.p.A. Business Overview
  34. 8.6.3 Italfarmaco S.p.A. Polycythemia Vera Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Italfarmaco S.p.A. Polycythemia Vera Drug Product Portfolio
  36. 8.6.5 Italfarmaco S.p.A. Recent Developments
  37. 8.7 Karus Therapeutics Limited
  38. 8.7.1 Karus Therapeutics Limited Company Information
  39. 8.7.2 Karus Therapeutics Limited Business Overview
  40. 8.7.3 Karus Therapeutics Limited Polycythemia Vera Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Karus Therapeutics Limited Polycythemia Vera Drug Product Portfolio
  42. 8.7.5 Karus Therapeutics Limited Recent Developments
  43. 8.8 miRagen Therapeutics, Inc.
  44. 8.8.1 miRagen Therapeutics, Inc. Company Information
  45. 8.8.2 miRagen Therapeutics, Inc. Business Overview
  46. 8.8.3 miRagen Therapeutics, Inc. Polycythemia Vera Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 miRagen Therapeutics, Inc. Polycythemia Vera Drug Product Portfolio
  48. 8.8.5 miRagen Therapeutics, Inc. Recent Developments
  49. 8.9 Nerviano Medical Sciences S.r.l.
  50. 8.9.1 Nerviano Medical Sciences S.r.l. Company Information
  51. 8.9.2 Nerviano Medical Sciences S.r.l. Business Overview
  52. 8.9.3 Nerviano Medical Sciences S.r.l. Polycythemia Vera Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Nerviano Medical Sciences S.r.l. Polycythemia Vera Drug Product Portfolio
  54. 8.9.5 Nerviano Medical Sciences S.r.l. Recent Developments
  55. 8.10 PharmaEssentia Corporation
  56. 8.10.1 PharmaEssentia Corporation Company Information
  57. 8.10.2 PharmaEssentia Corporation Business Overview
  58. 8.10.3 PharmaEssentia Corporation Polycythemia Vera Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 PharmaEssentia Corporation Polycythemia Vera Drug Product Portfolio
  60. 8.10.5 PharmaEssentia Corporation Recent Developments
  61. 8.11 Novartis AG
  62. 8.11.1 Novartis AG Company Information
  63. 8.11.2 Novartis AG Business Overview
  64. 8.11.3 Novartis AG Polycythemia Vera Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novartis AG Polycythemia Vera Drug Product Portfolio
  66. 8.11.5 Novartis AG Recent Developments
  67. 8.12 Teva Pharmaceutical Industries Ltd.
  68. 8.12.1 Teva Pharmaceutical Industries Ltd. Company Information
  69. 8.12.2 Teva Pharmaceutical Industries Ltd. Business Overview
  70. 8.12.3 Teva Pharmaceutical Industries Ltd. Polycythemia Vera Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Teva Pharmaceutical Industries Ltd. Polycythemia Vera Drug Product Portfolio
  72. 8.12.5 Teva Pharmaceutical Industries Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Polycythemia Vera Drug Value Chain Analysis
  2. 9.1.1 Polycythemia Vera Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Polycythemia Vera Drug Production Mode & Process
  6. 9.2 Polycythemia Vera Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Polycythemia Vera Drug Distributors
  9. 9.2.3 Polycythemia Vera Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst